arformoterol

DRUG5 trials

Sponsors

Sumitomo Pharma America, Inc., University of New Mexico, Dartmouth-Hitchcock Medical Center

Conditions

AsthmaChronic BronchitisChronic Obstructive Pulmonary DiseaseEmphysemaExercise-induced Bronchospasm

Phase 2

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

CompletedNCT00583947

Sumitomo Pharma America, Inc.Asthma

Start: 2008-01-31End: 2008-12-31Updated: 2012-02-22

Phase 3

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

CompletedNCT00064415

Sumitomo Pharma America, Inc.Chronic Bronchitis, Chronic Obstructive Pulmonary Disease, Emphysema

Start: 2002-06-30End: 2004-12-31Updated: 2012-02-22

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)

WithdrawnNCT00662779

University of New MexicoExercise-induced Bronchospasm

Start: 2008-04-30End: 2009-07-31Updated: 2015-12-11

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

CompletedNCT00909779

Sumitomo Pharma America, Inc.Chronic Obstructive Pulmonary Disease

Start: 2009-06-30End: 2012-06-30Updated: 2013-11-11

Unknown Phase

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

CompletedNCT01391559

Dartmouth-Hitchcock Medical CenterChronic Obstructive Pulmonary Disease

Start: 2011-07-31End: 2012-10-31Updated: 2013-08-07

Related Papers

One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD

UNC Libraries2020-11-01

Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.

2016-12-203 citations

One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.

2014-12-0117 citations